Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Cellectis S.A.NASDAQ: CLLS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $4.55M fell 7.7% year over year, behind the -2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.7% from the prior quarter. Over 3 fiscal years it compounded at +3.0% a year.

Context

  • Depreciation & amortization amounted to 27.6% of revenue in FY2025, down 20.2 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -7.7% toward the trailing-twelve-month pace of -2.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.55M-10.7% QoQ
Last fiscal yearDec 2025
$20.12M+1.4% YoY
LTMMar 2026
$19.68M-2.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.7%——
1 year+1.4%——
3-year CAGR+3.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
20.12M USD
Year-over-year change
+1.4%
4-year CAGR
+9.2%

Depreciation & Amortization vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.6% is the 7th highest of 9, against a peer median of +11.7%.
  • Depreciation & amortization amounts to 28.9% of revenue for CLLS, versus a peer median of 96.0%.
CLLS Competitors
Depreciation & Amortization for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+3.0%28.9%
KRROKorro Bio, Inc.LTM Mar 2026$3.75M USD-7.8%+14.7%97.6%
DBVTDBV Technologies S.A.LTM Mar 2026$3.14M USD+14181.8%-37.6%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.5M CHF+15.5%+0.4%69.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$1.23M USD—+8.0%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.18M USD+9.0%-11.2%236.0%
SLNSilence Therapeutics plcLTM Mar 2026$885K USD—-2.3%96.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026$674K USD+14.4%+24.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K USD+176.0%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
AMRNAmarin Corporation plcLTM Mar 2026$97.21K USD-103.3%-0.7%0.0%
Peer median (excluding CLLS) —+11.7%-0.7%96.0%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(96.75M)(98.69M)(116.84M)(36.7M)(67.8M)
Depreciation & Amortization14.16M18.44M18.52M19.84M20.12M
Deferred Income Tax087K371K00
Stock-Based Compensation11.49M6.04M5.23M00
Change in Working Capital(12.3M)(5.72M)(3.99M)53.57M(41.72M)
Accounts Receivables(12.44M)(8.99M)2.25M(6.72M)(4.44M)
Inventory215K0000
Accounts Payables177K3.25M(6.31M)2.05M(3.27M)
Other Working Capital(252K)23K67K58.24M(34.01M)
Other Non-Cash Items(21.17M)(7.6M)71.95M(14.61M)49.26M
Operating Cash Flow(104.56M)(87.44M)(24.75M)22.1M(40.14M)
Capital Expenditures(18.56M)(2.44M)(1.07M)(2.58M)(2.37M)
Acquisitions (Net)00000
Purchases of Investments(143K)00(162.48M)(160.27M)
Sales of Investments15M126K063.69M134.24M
Other Investing Activities10.97M(456K)(14.44M)00
Investing Cash Flow7.28M(2.76M)(15.51M)(102.63M)(29.58M)
Debt Repayment(10.64M)(6.6M)24.56M18.17M(5.4M)
Common Stock Issued44.64M067.94M82.68M44.14K
Common Stock Repurchased0(569K)000
Dividends Paid00000
Other Financing Activities13.53M8.32M(9.64M)(11.04M)(10.85M)
Financing Cash Flow47.53M1.15M82.87M89.8M(16.2M)
Effect of Forex Changes(5.75M)(3.36M)884K(2.73M)6.24M
Net Change in Cash(55.51M)(92.42M)43.49M6.54M(79.67M)
Free Cash Flow(123.12M)(89.89M)(25.82M)19.52M(42.5M)

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.